- Report
- October 2024
- 184 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- August 2024
- 149 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- June 2024
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- April 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,925GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- September 2023
- 180 Pages
Global
From €5416EUR$5,950USD£4,600GBP
- Report
- January 2024
- 206 Pages
Global
From €4050EUR$4,450USD£3,440GBP
- Report
- June 2022
- 320 Pages
Global
From €12651EUR$13,900USD£10,745GBP
- Report
- June 2023
- 280 Pages
Global
From €2275EUR$2,500USD£1,933GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more